Vivanza Biosci.

Why is Vivanza Biosciences Ltd falling/rising?

As of 10-Aug, Vivanza Biosciences Ltd's stock price is 1.88, down 0.53%. The decline is due to reduced investor participation and a year-to-date drop of 14.55%, despite recent short-term gains.

As of 10-Aug, Vivanza Biosciences Ltd's stock price is currently at 1.88, reflecting a decrease of 0.01 or 0.53%. This decline can be attributed to several factors. Although the stock has shown positive performance over the past week and month, with increases of 2.17% and 5.03% respectively, it has a year-to-date drop of 14.55%, indicating a longer-term downward trend. <BR><BR>Additionally, the stock's performance today is described as inline with the sector, but it is important to note that investor participation has fallen significantly, with delivery volume decreasing by 58.37% compared to the 5-day average. This reduced interest from investors could contribute to the stock's current decline. <BR><BR>Moreover, while the stock is trading higher than its 5-day, 20-day, and 50-day moving averages, it remains below its 100-day and 200-day moving averages, suggesting that the stock may be underperforming in the longer term. Overall, the combination of declining investor participation and the stock's historical performance indicates a challenging environment for Vivanza Biosciences Ltd, leading to its current price drop.

Which are the latest news on Vivanza Biosci.?

Should I buy, sell or hold Vivanza Biosciences Ltd?

When is the next results date for Vivanza Biosciences Ltd?

The next results date for Vivanza Biosciences Ltd is August 1, 2026.

The next results date for Vivanza Biosciences Ltd is scheduled for August 1, 2026.

How big is Vivanza Biosci.?

As of 10th June, Vivanza Biosciences Ltd has a market capitalization of 7.00 Cr, with recent net sales of 115.91 Cr and a net profit of 0.40 Cr. Shareholder's funds are 3.96 Cr, and total assets are valued at 16.45 Cr.

As of 10th June, Vivanza Biosciences Ltd has a market capitalization of 7.00 Cr, categorized as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 115.91 Cr and a Net Profit of 0.40 Cr.<BR><BR>For the reporting period of March 2025, Shareholder's Funds amounted to 3.96 Cr, while Total Assets were valued at 16.45 Cr.

Who are in the management team of Vivanza Biosci.?

The management team of Vivanza Biosci includes Hemant Parikh (Director), Sunil Shah (Independent Director), Avinash G. Bhojwani (Company Secretary & Compliance Officer), Apeksha Vyas (Independent Director), and Jayendra Mehta (Managing Director).

The management team of Vivanza Biosci includes the following individuals:<BR><BR>1. Hemant Parikh - Director<BR>2. Sunil Shah - Independent Director<BR>3. Avinash G. Bhojwani - Company Secretary & Compliance Officer<BR>4. Apeksha Vyas - Independent Director<BR>5. Jayendra Mehta - Managing Director<BR><BR>If you need more specific details about their roles or backgrounds, feel free to ask!

Who are the peers of the Vivanza Biosci.?

Vivanza Biosci.'s peers include Beryl Drugs, Unjha Formul., Ganga Pharma., Decipher Labs, Brawn Biotech, Shyama Computro., Fabino Enter, and Saroja Pharma In. Vivanza has an average growth rating and a 1-year return of -29.75%, better than Genomic Valley but worse than Beryl Drugs, which has the highest return at 31.73%.

Peers: The peers of Vivanza Biosci. are Beryl Drugs, Unjha Formul., Ganga Pharma., Decipher Labs, Brawn Biotech, Shyama Computro., Fabino Enter, and Saroja Pharma In.<BR><BR>Quality Snapshot: Below Average management risk is observed at Beryl Drugs, Ganga Pharma., Decipher Labs, Brawn Biotech, and Fabino Enter, while Average management risk is found at Unjha Formul. and Saroja Pharma In. Vivanza Biosci. has an Average growth rating, while Below Average growth is noted for Beryl Drugs, Ganga Pharma., Decipher Labs, Brawn Biotech, Unjha Formul., and Fabino Enter, and the rest. Good capital structure is seen at Unjha Formul., while Below Average capital structure is present at Beryl Drugs, Ganga Pharma., Decipher Labs, Vivanza Biosci., Brawn Biotech, Fabino Enter, and the rest.<BR><BR>Return Snapshot: Beryl Drugs has the highest 1-year return at 31.73%, while Genomic Valley has the lowest at -41.91%. Vivanza Biosci.'s 1-year return of -29.75% is better than Genomic Valley's but worse than Beryl Drugs. Additionally, Ganga Pharma., Decipher Labs, and Brawn Biotech have negative six-month returns.

What does Vivanza Biosci. do?

Vivanza Biosciences Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, focusing on providing global quality pharmaceutical products. As of March 2026, it reported net sales of 6 Cr and a market cap of INR 7 Cr.

Overview:<BR>Vivanza Biosciences Ltd operates in the Pharmaceuticals & Biotechnology industry as a micro-cap company, focusing on providing global quality pharmaceutical products at competitive prices.<BR><BR>History:<BR>Vivanza Biosciences Ltd was incorporated in March 1982 and transitioned from a Private Limited Company to a Public Limited Company in May 1992. The company was re-established in April 2016 with a focus on expanding its presence in the global market. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 6 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 17.00<BR>- Industry P/E: 32<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 2.32<BR>- Return on Equity: 9.17%<BR>- Price to Book: 1.61<BR><BR>Contact Details:<BR>Address: 403 Sarthik 2 Opp Rajpath Club, S G Highway Ahmedabad Gujarat : 380054<BR>Tel: 91-07405699869<BR>Website: http://www.vivanzabiosciences.com

Are Vivanza Biosciences Ltd latest results good or bad?

Vivanza Biosciences Ltd's latest results are concerning, showing a net loss of ₹0.45 crores and an 85.94% drop in revenue quarter-over-quarter, despite a year-on-year revenue growth of 1,225%. The company's lack of profitability and negative operating margins raise doubts about its business sustainability, leading to a 5% decline in stock price post-announcement.

Vivanza Biosciences Ltd's latest results indicate a challenging situation for the company. In Q4 FY26, the company reported a net loss of ₹0.45 crores, which is a significant decline of 325% compared to the previous quarter. Additionally, revenue fell sharply by 85.94% quarter-over-quarter to ₹6.36 crores, although it did show an impressive year-on-year growth of 1,225% from ₹0.48 crores in Q4 FY25.<BR><BR>Despite the explosive year-on-year revenue growth, the company is currently loss-making and has negative operating margins of -3.77%. This raises concerns about the sustainability of its business model and its ability to convert revenue growth into consistent profitability. The stock price has also reacted negatively, dropping 5% following the results announcement, and it has declined 13.64% year-to-date.<BR><BR>Overall, while there are signs of significant revenue expansion, the lack of profitability and operational challenges suggest that the latest results are more concerning than positive. Investors are advised to be cautious given the company's current financial instability and volatility.

How has been the historical performance of Vivanza Biosci.?

Vivanza Biosci. experienced significant financial declines, reporting net sales of 7.42 Cr in March 2025, down from 27.84 Cr in March 2024, resulting in a loss with a profit after tax of -0.67 Cr. The company faced negative cash flow and decreased total assets and liabilities during this period.

Answer:<BR>The historical performance of Vivanza Biosci. shows significant fluctuations in its financial metrics over the years, culminating in a loss in the most recent fiscal year.<BR><BR>Breakdown:<BR>Vivanza Biosci. reported net sales of 7.42 Cr in March 2025, a sharp decline from 27.84 Cr in March 2024 and 17.81 Cr in March 2023. The total operating income mirrored this trend, dropping to 7.42 Cr in March 2025 from 27.84 Cr in the previous year. Total expenditure also decreased to 7.79 Cr in March 2025 from 26.77 Cr in March 2024. Operating profit (PBDIT) turned negative at -0.31 Cr in March 2025, following a profit of 1.12 Cr in March 2024. Consequently, the profit before tax fell to -0.67 Cr in March 2025, down from 0.70 Cr in March 2024, leading to a profit after tax of -0.67 Cr compared to a profit of 0.55 Cr in the prior year. The company's total liabilities decreased to 16.45 Cr in March 2025 from 19.50 Cr in March 2024, while total assets also fell to 16.45 Cr from 19.50 Cr. Cash flow from operating activities was negative at -2.00 Cr in March 2025, contrasting with a positive cash flow of 2.00 Cr in March 2024. Overall, the financial performance indicates a challenging year for Vivanza Biosci., marked by declining revenues and profitability.

Who are the top shareholders of the Vivanza Biosci.?

The top shareholders of Vivanza Biosci are Parth Hemant Parikh with 19.77%, Ashoka Metcast Limited with 3.85%, and individual investors who collectively own 73.69%. There are no institutional investors or mutual funds involved.

The top shareholders of Vivanza Biosci include Parth Hemant Parikh, who holds the highest stake at 19.77%. The next significant public shareholder is Ashoka Metcast Limited, with a holding of 3.85%. Additionally, individual investors collectively hold a substantial 73.69% of the company's shares. There are no institutional investors or mutual funds involved in the shareholding.

Is Vivanza Biosci. overvalued or undervalued?

As of May 13, 2025, Vivanza Biosci. is considered risky and overvalued due to a negative PE ratio of -9.52, an EV to EBIT of -18.05, and a ROE of -16.92%, significantly underperforming compared to its peers, with a 59.33% decline in stock performance over the past year.

As of 13 May 2025, the valuation grade for Vivanza Biosci. has moved from attractive to risky, indicating a significant shift in the company's perceived value. The company is currently considered overvalued, given its negative PE ratio of -9.52 and an EV to EBIT of -18.05, which highlight underlying financial distress. Additionally, the ROE stands at -16.92%, further emphasizing the challenges faced by the company.<BR><BR>In comparison to its peers, Vivanza Biosci. lags significantly behind. For instance, Altius Telecom, rated very attractive, boasts a PE ratio of 52.97, while other peers like Embassy Office REIT and Inventurus Knowledge are categorized as very expensive with PE ratios of 23.06 and 56.63, respectively. The stark contrast in these ratios suggests that Vivanza Biosci. is not only underperforming but also carries a higher risk profile relative to its industry counterparts. Recent stock performance shows a decline of 59.33% over the past year, contrasting sharply with the Sensex's return of 7.65%, reinforcing the notion of overvaluation.

What is the technical trend for Vivanza Biosci.?

As of June 4, 2025, Vivanza Biosci's trend has shifted to mildly bearish, indicated by daily moving averages and weekly RSI, despite a mildly bullish weekly MACD, with overall indicators suggesting weakness and significant underperformance over the past year.

As of 4 June 2025, the technical trend for Vivanza Biosci has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. Although the weekly MACD is mildly bullish, the overall indicators, including the Bollinger Bands and KST on a monthly basis, suggest weakness. The Dow Theory indicates no clear trend in both weekly and monthly perspectives. The stock has underperformed significantly over the past year, further supporting the bearish outlook.

Has Vivanza Biosci. declared dividend?

No Dividend History Available